MARY RICHARDSON: Open Payments
NPI 1528044492 · RARITAN, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,235 in 97 payments from 15 companies in 2025. Trend: 2023 $2,571 · 2024 $1,979 · 2025 $2,235
Food & beverage: $2,235
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 15 | $330 |
| Axsome Therapeutics, Inc. | 7 | $312 |
| ABBVIE INC. | 21 | $292 |
| Vanda Pharmaceuticals Inc. | 5 | $266 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $258 |
| Janssen Pharmaceuticals, Inc | 8 | $228 |
| E.R. Squibb & Sons, L.L.C. | 12 | $149 |
| Lundbeck LLC | 7 | $118 |
| Teva Pharmaceuticals USA, Inc. | 4 | $68 |
| Bausch Health US, LLC | 4 | $65 |
Products named: REXULTI, Auvelity, VRAYLAR, FANAPT, CAPLYTA, COBENFY, SPRAVATO, INVEGA SUSTENNA.
Industry payments across NJ — which companies pay providers there.
